This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
by Zacks Equity Research
Haemonetics (HAE) receives FDA clearance for the advancements made to the NexSys PCS plasma collection system.
CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs
by Zacks Equity Research
CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.
STERIS (STE) Buys Surgical Instrumentation Platform From BDX
by Zacks Equity Research
STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.
Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches
by Zacks Equity Research
Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
by Zacks Equity Research
NSPCA is also working on recommending SenesTech's (SNES) ContraPest to private and state entities and to assist with regulatory issues.
Insulet (PODD) Launches the Omnipod 5 AID System in the UK
by Zacks Equity Research
Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.
Why You Should Retain Walgreens Boots (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection
by Zacks Equity Research
The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
CVS Health (CVS) Invests in Renewable Energy With New Pact
by Zacks Equity Research
CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).
Encompass Health's (EHC) 158th Hospital Opens in Maryland
by Zacks Equity Research
The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
by Zacks Equity Research
Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe
by Zacks Equity Research
Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
by Zacks Equity Research
Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
by Zacks Equity Research
Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.